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popliteal arteries: A reappraisal after 44 months’
experience
Russell H. Samson, MD, RVT, David P. Showalter, MD, Michael Lepore Jr, MD,
Deepak G. Nair, MD, RVT, and Kathy Merigliano, RVT, Sarasota, Fla
Objectives: Long-term patency remains a significant hurdle in the minimally invasive treatment of arteriosclerosis in the
superficial femoral (SFA) and popliteal arteries. CryoPlasty therapy (PolarCath, Boston Scientific Corp, Natick, Mass) is
a novel approach designed to significantly reduce injury, elastic recoil, neointimal hyperplasia, and constrictive remod-
eling. The technique combines the dilatation forces of percutaneous transluminal angioplasty (PTA) with cold thermal
energy applied to the plaque and vessel wall. We previously reported a technical success rate of 96% and a 12-month
freedom from restenosis rate of 82.2%. However, a review of the original cohort supplemented by experience with a
further 47 lesions has demonstrated less desirable results.
Methods: FromDecember 2003 through July 2007, 92 lesions in 64 consecutive patients were treated and followed up for
a median of 16 months with statistically significant follow-up at 24 months.
Results: The immediate technical success rate was 88%. Nine stents were immediately required after unsuccessful
CryoPlasty (9.8%) five of which were as a result of a dissection. No unanticipated adverse events occurred, specifically, no
thrombus, acute occlusions, distal embolizations, aneurysms, or groin complications. Vascular calcification was respon-
sible for technical failure in six of the 11 immediately unsuccessful procedures. Freedom from restenosis for successfully
treated lesions was 57% and 49% at 12 and 24 months, respectively. CryoPlasty of heavily calcified lesions, vein graft
lesions, and in-stent stenosis faired poorly. Excluding these lesions from analysis would have resulted in an immediate
success of 94% (81 of 86) and freedom from restenosis of 61% and 52% at 12 and 24 months, respectively. However, on
an intention-to-treat basis, freedom from restenosis was 47% and 38% at 12 and 24 months, and CryoPlasty added
approximately $1700 to the cost of each procedure.
Conclusion: Analysis of this expanded, longer-term data suggests that our earlier, smaller study provided an overly
optimistic appraisal of the benefits of CryoPlasty. It is possible that a larger analysis might have identified a subset of
patients or lesions that would benefit from CryoPlasty, but considering the additional cost, we no longer use this
technique in our practice. ( J Vasc Surg 2008;48:634-7.)Although minimally invasive treatment of atherosclerotic
lesions in the superficial femoral (SFA) and popliteal arteries
maybepreferred to surgery, percutaneous transluminal angio-
plasty (PTA) and stenting are problematic, with 1-year reste-
nosis rates as high as 60%.1 Various alternatives have been
advanced, including drug-eluting stents, atherectomy, laser-
assisted angioplasty, endovascular grafts, and brachytherapy,
but all pose problems and have cost consequences that poten-
tially limit their use. Recent concerns about stent fractures and
the clinical implications associated with them further drive the
need for alternative therapeutic options.2,3
In an effort to achieve longer-term patency while min-
imizing the use of stents, a novel form of angioplasty, called
CryoPlasty therapy (PolarCath Peripheral Dilatation Sys-
tem; Boston Scientific Corp, Natick, Mass), was intro-
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634duced. CryoPlasty therapy builds on conventional PTA by
applying cold thermal energy to the plaque and vessel wall.4
Rather than saline, liquid nitrous oxide is used to inflate the
balloon, cooling the surface temperature of the balloon to
10°C. The cooling is associated with three vascular effects
that may contribute to improved acute and long-term
outcomes by affecting processes implicated in restenosis:
altered plaque response which makes plaque more vulner-
able to dilation, reduced elastic recoil, and induction of
apoptosis (noninflammatory cell death) in the smoothmus-
cle cells.
We have previously published the early (12-month) pa-
tency results of our single-center experiencewithCryoPlasty.5
This initial experience with 47 lesions demonstrated a techni-
cal success rate of 96%, with no dissections and a stent rate of
8.5%. Freedom from restenosis at 12 months was 82.2%.
Because of these excellent results, we continued to use
CryoPlasty routinely for a further 45 lesions in the superfi-
cial femoral, popliteal, and tibioperoneal trunk arteries as
well as for stenoses in lower extremity vein bypass grafts and
now have an experience spanning 44 months. A review of
this enlarged patient cohort has demonstrated different
results than those previously reported and prompts this new
report.
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Patients. From December 2003 through July 2007,
64 consecutive patients (71 procedures, 67 limbs, 92 le-
sions) were treated using CryoPlasty therapy. Concurrent
with this study, our group also used other endovascular
techniques such as atherectomy and subintimal angioplasty.
However, to evaluate this new technique, we studied the
procedure only in patients that we otherwise would have
treated with balloon angioplasty and never used CryoPlasty in
conjunction with these other techniques. Of the 92 lesions
treated, 61 (67%) were in the SFA, 25 (27%) were popliteal,
and six (6%) were in an autogenous nonreversed vein bypass
graft.
The 64 patients (31 women and 33 men) were a
mean age of 81 years (range, 55-95 years). Indications
for treatment with CryoPlasty therapy were gangrene in
3, rest pain in 3, failing femoropopliteal graft in 11, skin
ulceration in 7, and claudication in 49 (Table I). Five
procedures were performed for restenosis after previous
standard PTA. Two CryoPlasty procedures were for an
in-stent stenosis. Some CryoPlasty treatments were per-
formed for more than one indication. Comorbid condi-
tions and risk factors, as determined by the Society for
Vascular Surgery classifications,6 are summarized in Ta-
ble II.
Technique. Arterial access was achieved by using 6F
or 7F sheaths placed through the contralateral groin
except in one patient in whom an ipsilateral approach was
used. Balloon lengths varied, depending on the length of
the artery to be treated (2 to 6 cm), with the 2-cm and
4-cm balloon being used predominantly. According to
the manufacturer, the CryoPlasty balloons are inflated to
8 atm of pressure. It is recommended that the treated
area extend several millimeters beyond the lesion to help
minimize dissections, because the effect of the cold
temperature on healthy tissue has been demonstrated to
have no negative effect.7 Balloon diameter also varied,
but usually was chosen to equal the size of the artery on
a case-by-case basis. Overdilation was avoided, in accor-
dance with our protocol of using a balloon diameter
equal to the width of the normal artery and not overin-
flating, as we may do with standard balloons. This deci-
sion is predicated on the possible benefit CryoPlasty
therapy may offer by not causing cell injury but rather
Table I. Indications for CryoPlastya for failing
femoropopliteal bypass grafts
Indication Cases, No.
Valve cusp stenosis 1
Anastomotic stenosis 2
In-graft stenosis 3
Inflow stenosis 4
Outflow Stenosis 2
aPolarCath, Boston Scientific Corp, Natick, Mass.resulting in apoptosis, a pathway that may lead to thedevelopment of less scar tissue or neointimal hyperplasia,
or both.
All patients received intravenous heparin at a dose of
3000 to 5000 U. Reversal with protamine was at the
discretion of the treating interventionalist. Manual com-
pression was used to achieve groin hemostasis in all pa-
tients. All patients were prescribed aspirin (81 mg). All
patients were followed up with duplex ultrasound (DUS)
imaging and ankle-brachial pressure index (ABI) measure-
ment in an InterSocietal Commission for the Accreditation
of Vascular Laboratories (ICAVL) accredited vascular lab.
Studies were performed 1 month of the procedure and
then every 6 months thereafter. The treatment site was
specifically recorded at the time of the original pretreat-
ment DUS scan so that subsequent DUS studies could
specifically evaluate that location.
A lesion was considered to be significant if it produced
a velocity of 300 cm/s or a doubling of velocity compared
with the flow velocity immediately proximal to the lesion, or
both. Lesionswere also graded according to theTransAtlantic
InterSociety Consensus Classification (TASC) II. The loca-
tion of the stenosis was recorded in centimeters from the
femoral bifurcation by DUS evaluation and confirmed on
arteriography using a radiopaque ruler placed between the
patient’s legs.
In our previous article, a restenosis was considered to
have occurred when the post-CryoPlasty DUS scan identi-
fied a return to, or progression beyond, the velocity en-
countered immediately before the procedure. In this ex-
panded study we refer to those criteria as defining
“recurrence” and now define “restenosis” according to the
more accepted definition of a velocity profile again 300
cm/s or a demonstrated doubling of velocity across the
lesion, or both. All lesions that were subsequently treated
for recurrence had confirmatory arteriographic confirma-
tion. However, the indication for treatment was always
based on clinical indications and not DUS, ABI, or arterio-
graphic evidence of restenosis alone.
Statistical analysis. All patients were entered into a
computerized registry (AtriumNetMD, Nashua, NH). The
MedCalc 9.4.1.0 statistical software (MedCalc Software,
Mariakerke, Belgium) was used to perform multivariate
analysis of variables using Cox proportional hazards regres-
Table II. Comorbid conditions and risk factors
History
Patients,
No (%)
Level 1,
No.
Level 2,
No.
Level 3,
No.
Diabetes 22 (34) 9 13 0
Hypertension 47 (73) 20 22 5
Tobacco 24 (38) 15 7 2
Cardiac disease 29 (45) 6 16 7
Carotid disease 42 (66) 23 19 0
Renal disease 5 (8) 3 0 2
Hyperlipidemia 43 (67) 12 19 12
Pulmonary disease 9 (14) 1 1 0sion and to construct Kaplan-Meier curves.
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The mean follow-up was 16 months (range, 1 day-44
months). Statistically significant Kaplan-Meier curves are
available for 24 months. After undergoing CryoPlasty ther-
apy, 11 patients died of causes unrelated to the procedure.
No patient has been lost to follow-up.
The procedure was performed on a median of 1.5 lesions
per limb (range, 1-3 lesions). Mean lesion length for the 92
lesions was 3.9 cm (range, 0.5-45 cm). Most of the lesions
were TASCA, except for 11TASCB lesions and oneTASCC
lesion. Total occlusions were not treated in this series. On
average there were two tibial runoff arteries (no runoff artery
in 4 procedures, 1 artery in 30 procedures, 2 arteries in 25
procedures, and 3 arteries in 12 procedures).
The immediate technical success rate, defined as a residual
stenosis of 30%, was 88% (81 of 92 lesions). Excluding the
technical failures, the mean residual stenosis was 23.2%, al-
though three lesions had a 30% residual stenosis. There were
11 immediately unsuccessful CryoPlasty procedures, and the
cause of these failures is tabulated in Table III. Seven dissec-
tions occurred, of which five were stented and two were left
untreated; both of the latter have remained patent. There
were no acute occlusions and no adverse events such as
thrombus, distal embolization, aneurysm, or local groin
complications. All successfully treated patients were symp-
tomatically improved, and no immediate surgical or endo-
vascular interventions or amputations were required. The
overall lesion stent rate was 9.8% (9 of 92 lesions).
The mean ABI was 0.73 (range, 0.31-1.03) before
treatment and 0.89 (range 0.49-1.11) after treatment. At
the initial follow-up, 28 of 67 limbs (42%) showed im-
provement of ABI. Vascular calcification causing incom-
pressible arteries, pretreatment ABI of 0.85, and mul-
tiple areas of stenosis or occlusion limit the value of
post-treatment ABI as a measure of technical success.
At 1 month after the procedure, DUS scans of all
successfully dilated lesions showed marked improvement,
with velocity profiles demonstrating absence of hemody-
namic compromise (ie, no doubling of velocity across the
lesion or velocity of 300 mL/s).
Two CryoPlasty procedures were for an in-stent steno-
sis, one of which restenosed in 4 months and the other in
12 months. Overall, 36 (39%) lesions have subsequently
Table III. Immediate technical failures after CryoPlastya
Event No.
30% residual stenosis requiring standard balloon
angioplasty 1
Unresponsive heavily calcified lesion requiring
femoropopliteal bypass 1
Unresponsive heavily calcified lesion requiring stent 2
Dissection requiring stent for salvageb 5
Unresponsive non-calcified lesion requiring a stent 2
aPolarCath, Boston Scientific Corp, Natick, Mass.
bThree of the five were calcified lesions.recurred. On an intention-to treat basis, Kaplan-Meierfreedom from restenosis was 47% and 38% at 12 and 24
months, respectively (Fig). However, freedom from reste-
nosis for successfully treated lesions (ie, excluding the 2
unsuccessful lesions and those that required immediate
stents) was 56% and 48% at 12 and 24 months. For com-
parison with our previous manuscript, freedom from recur-
rence was 59% and 48% at 12 and 24 months. Target lesion
revascularization after successful revascularization was 23%
and 30% at 12 and 24 months. Multivariate analysis of
variables including risk factors for atherosclerosis, lesion
characteristics, and runoff vessels failed to identify any
variable or group of variables that would predict restenosis.
DISCUSSION
Endovascular therapies for stenosis/occlusions of the
superficial femoral and popliteal arteries remain disappoint-
ing, with reported 2-year patency rates of 40% to 60%.1
Although some proponents of stents suggest improved
results, many interventionalists believe that stents offer
patency rates no better that a good angioplasty. Newer
techniques such as laser ablation and CryoPlasty were her-
alded as potential improvements.4 Our own 1-year 82.2%
rate of freedom from restenosis with CryoPlasty therapy
was also encouraging and suggested that this new proce-
dure may be an advance over conventional PTA and stent-
ing.5 Also, a recent Cochrane review concluded that al-
though no randomized controlled trials exist to properly
evaluate this method, technical success and early primary
patency results may suggest a future role for CryoPlasty in
the treatment of peripheral arterial disease.8 However, with
increased experience and longer follow-up, our results ap-
pear to show no added benefit for CryoPlasty.
The immediate success rate in our series was only 88%,
and freedom from restenosis for successfully dilated lesions
at 12 and 24 months was only 57% and 49%. These results
are very similar to those reported with standard balloon
Fig. This Kaplan-Meier curve for freedom from restenosis was calcu-
lated based on intention to treat and includes all 92 procedures. The
12-month and 24-month freedom from restenosis is 47% and 38%,
respectively. The curves lose statistical validity after 24 months.angioplasty. On the basis of intention to treat, the results of
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month freedom from restenosis of only 47% and 38%.
Freedom from target lesion revascularization rates were
certainly commendable, but it must be realized that this
measure of success does not necessarily imply benefit from
the procedure, because many patients with restenosis were
either unaware of the recurrence (it being found only by
testing) or chose not to have, nor required, further therapy.
Treatment for restenosis was only offered if the patients
became symptomatic to a degree that they requested rein-
tervention or bypass.
We have analyzed our expanded data to try to deter-
mine if there is an explanation for why the expanded patient
experience demonstrates poorer 12-month data than orig-
inally reported. From this review it has become apparent
that arterial calcification may be the Achilles heel of these
procedures. If the six calcified lesions that were unrespon-
sive or required a stent had been excluded, the immediate
success rate would have been 94%, essentially the same as
originally reported. Further, heavy vascular calcification as
evidenced by dense opacification of the arterial wall on
noncontrast arteriography was present in eight lesions that
were adequately treated and three restenosed 6 months.
To evaluate CryoPlasty of only straightforward, non-
calcified atherosclerotic lesions, we recalculated the data
excluding all calcified lesions, in-stent stenosis, and vein
graft lesions. The Kaplan-Meier freedom from restenosis
for successfully dilated lesions would have been only mod-
estly improved (61% and 52% at 12 and 24 months).
However, multivariate analysis of variables including risk
factors and lesion characteristics (including calcification)
failed to define a predictor for restenosis. Further, TASC II
classification also did not impact restenosis. Of the 11
TASC B and one TASC C lesions, six restenosed—but
all 6 months—and seven restenosed at 2 years after
CryoPlasty. We currently have no explanation for the 23%
disparity in 12-month recurrence rate between the ex-
panded and original Kaplan-Meier curves other than to
suggest that the number of lesions in our original data set
was too small.
Because CryoPlasty seems to offer no long-term benefit
compared with standard balloon angioplasty, we have re-
considered its role in our practice. An important consider-
ation, however, is the low dissection rate (7.6%) that we and
others5,4 have proposed may be a reason to continue using
this procedure. A low dissection rate should theoretically
translate into better early patency and decrease the need
for costly stents. Indeed, only five stents were required for
seven dissections, and three of these were in calcified
lesions that we now would not consider appropriate for
CryoPlasty. However, because CryoPlasty costs an average
of $1700 per procedure, we believe it does not make
economic sense to continue using CryoPlasty on all lesions
simply to reduce the need for a few costly stents.
CONCLUSION
Evaluation of the clinical benefit of any new endovas-
cular technique for the treatment of atherosclerotic lesionsof the infrainguinal arteries needs to answer four salient
questions: first, does the procedure decrease the extent of
stenosis; second, is this result durable; third, does it pro-
duce clinically relevant results and: fourth, is it cost effec-
tive? Our data demonstrate that CryoPlasty can dilate most
lesions, but calcified lesions respond poorly and 12% of
dilations were immediately unsuccessful. The proponents
of CryoPlasty would suggest that apoptosis improves dura-
bility by preventing restenosis. However, long-term pa-
tency of successfully dilated lesions was no better than
reported rates for standard balloon angioplasty, with free-
dom from restenosis of only 57% at 12 months and 49% at
24 months. Some may infer that the low target lesion
revascularization rate implies clinical relevance, but this is a
poor outcome measure because it is often unrelated to the
success or failure of the original CryoPlasty. Of greater
clinical significance were the poor intention-to-treat rates
of freedom from restenosis of 47% at 12 months and 38% at
24months. Finally, because CryoPlasty adds approximately
$1700 to the cost of the procedure, it cannot be considered
cost-effective. Accordingly, we have stopped using this
technology in our practice.
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